Core Viewpoint - AtaiBeckley NV has appointed Michael Faerm as chief financial officer, effective March 9, 2026, to enhance its financial strategy as it advances its mental health treatment pipeline [1]. Group 1: Appointment Details - Michael Faerm brings over 25 years of experience in life sciences, equity research, and investment banking [1]. - Faerm's previous roles include CFO at Viracta Therapeutics and interim CFO at Harpoon Therapeutics, which was acquired by Merck [2]. - He has also held positions at Innoviva, Forest Laboratories, and Regeneron Pharmaceuticals, focusing on business development and strategic finance [2]. Group 2: Financial Strategy and Leadership Transition - Faerm will oversee the company's financial strategy, capital markets activities, and overall financial operations [1]. - Current CFO Anne Johnson will transition to chief accounting officer, continuing to lead accounting and financial operations while supporting Faerm [3]. - The CEO of AtaiBeckley, Srinivas Rao, emphasized the importance of Faerm's strategic finance background as the company advances its lead candidate BPL-003 toward Phase 3 [4]. Group 3: Future Outlook - Faerm expressed enthusiasm about joining AtaiBeckley at a pivotal time, with BPL-003 advancing and a strong clinical-stage pipeline [5]. - He looks forward to collaborating with Johnson and the leadership team to support the company's late-stage development [6].

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investm ...

Core Insights - Merck announced positive new data for ENFLONSIA™ (clesrovimab), indicating its effectiveness for infants and children under 2 years old at increased risk for severe RSV over two RSV seasons [1] Group 1 - The data highlights the potential of ENFLONSIA™ to significantly reduce the risk of severe respiratory syncytial virus (RSV) in vulnerable pediatric populations [1] - The announcement is expected to enhance Merck's position in the pediatric infectious disease market, particularly in the context of RSV treatment [1] - This development may lead to increased interest from healthcare providers and potential partnerships for further research and distribution [1]

European stocks closed on a firm note on Wednesday, reacting to some encouraging earnings updates and economic data from the region, and on expectations of more monetary easing by a few central banks. Easing geopolitical tensions contributed as well to the positive mood in the .Soft inflation data from both France and the UK helped. Investors also reacted to reports of a leadership change at the European Central Bank. A Financial Times report said Christine Lagarde plans to leave the European Central Bank ...

Core Insights - Merck & Co. Inc. has announced a strategic collaboration with Mayo Clinic to utilize artificial intelligence and advanced analytics in drug discovery, aiming to enhance the development of tailored therapies [1][2] - This partnership is significant as it marks Mayo Clinic's first strategic partnership of this scale with a global biopharmaceutical company, indicating a major step in integrating clinical data with AI capabilities [2] Drug Development Focus - The collaboration will initially target high-need therapeutic areas, including inflammatory bowel disease, atopic dermatitis, and multiple sclerosis, where advanced analytics can facilitate the development of more effective therapies [3] Technical Analysis - Merck's stock is currently trading 6.1% above its 20-day simple moving average and 11.4% above its 100-day simple moving average, indicating longer-term strength [4] - The stock has increased by 45.96% over the past 12 months and is closer to its 52-week highs than lows, with an RSI of 69.33 and a bullish MACD [4] Sector Performance - Merck is underperforming its sector, with shares down 0.30% while the healthcare sector remained flat on the previous trading day, although the sector has shown a 1.27% increase over the past 30 days [5][6] Analyst Consensus - The stock carries a Buy Rating with an average price target of $119.95, with recent analyst actions including upgrades from Guggenheim to a target of $140.00 and Citigroup to $120.00 [6][8] - The Benzinga Edge scorecard indicates that while Merck has strong momentum, it is trading at a steep premium relative to peers, suggesting a need for caution [9] Price Action - At the time of publication, Merck shares were down 0.81% at $120.59, approaching its 52-week high of $123.33 [10]

regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new informati ...

Teva Pharmaceutical Industries (NYSE:TEVA) Update / briefing February 17, 2026 08:00 AM ET Company ParticipantsChristopher Stevo - SVP of Investor RelationsEric Hughes - CMOGlenn Santangelo - Managing DirectorJason Gerberry - Managing DirectorMatt Dellatorre - Vice PresidentRichard Francis - CEOUmair Rafat - Senior Managing DirectorConference Call ParticipantsAsh Verma - Stock AnalystDavid Amsellem - Senior Research AnalystDennis Ding - Stock AnalystLes Salewski - Stock AnalystLouise Chen - Wall Street Anal ...

Key Takeaways Merck projects over $70B in pipeline opportunities by mid-2030s beyond the Keytruda LOE.MRK's Capvaxive, Winrevair and Welireg delivered solid 2025 sales amid strong ongoing launches.Merck's phase III pipeline has nearly tripled since 2021, aided by M&A and new approvals.Merck (MRK) announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both earnings and sales. Importantly, on the fourth-quarter conference call, management provided an enco ...

Key Takeaways Merck stock rose 7.4% in a month after beating Q4 earnings and sales estimates.MRK's 2026 outlook missed expectations, with EPS set to fall on higher M&A charges.Keytruda patent loss, Gardasil slump in China and the $2.5B generic hit weigh on near-term growth.Merck’s (MRK) stock has risen 7.4% in the past month. A key driver of the increase was better-than-expected fourth-quarter results and a more confident outlook for its future growth.In the fourth quarter, Merck beat estimates for both ear ...

AbbVie Conference Call Summary Company Overview - **Company**: AbbVie (NYSE: ABBV) - **Date**: February 13, 2026 - **Focus**: Discussion on drug development, particularly lutikizumab and RINVOQ for hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD) Key Points Drug Development and Differentiation - **Lutikizumab and RINVOQ**: Targeting HS with a distinct mechanism involving IL-1 alpha and IL-1 beta, aiming for clinical differentiation from HUMIRA and Cosentyx [1][2] - **Clinical Data**: Phase II data shows strong efficacy in both biologic-experienced and naive patients, indicating potential for differentiation in treatment outcomes [13][21] - **Combination Therapies**: AbbVie is exploring co-formulations and combinations with other assets to enhance treatment efficacy [7][9] Clinical Insights - **Neutrophil Role in HS**: Lutikizumab's bispecific approach targets both IL-1 alpha and beta, which play crucial roles in HS pathology [11][43] - **Efficacy Expectations**: Conventional wisdom suggests biologic-naive patients may show higher efficacy, but AbbVie has observed clinically meaningful effects in TNF-failure populations [17][21] Competitive Landscape - **Other Compounds**: AbbVie is aware of competitors like Sanofi's OX40 bispecific and their implications in HS treatment, particularly regarding immunosuppression risks [23][28] - **Immunogenicity Concerns**: Challenges with anti-TNF bispecifics have been noted, leading AbbVie to focus on novel mechanisms rather than traditional anti-TNFs [34][36] IBD Development - **SKYRIZI and Combinations**: AbbVie is excited about the potential of SKYRIZI in IBD, particularly with combinations involving lutikizumab and TL1A-directed treatments [45][49] - **TREM1 Mechanism**: TREM1 is being evaluated as a novel mechanism for IBD, with potential applications in other fibrotic diseases [60][78] Future Directions - **Biomarker Research**: AbbVie is investigating biomarkers to enhance individualized treatment approaches in IBD, aiming for more targeted therapies [69][70] - **TL1A in Fibrotic Diseases**: The potential for TL1A as an anti-fibrotic agent is being explored, with interest in diseases like rheumatoid arthritis and systemic sclerosis [78][80] Oral IL-23 Development - **Next-Generation Oral Treatments**: AbbVie is developing an oral IL-23 treatment, focusing on higher potency and longer half-life to improve patient adherence compared to existing therapies [81][83] Unique Compounds - **ADC Targeting CD19**: AbbVie is excited about a unique ADC targeting CD19 with a steroid payload, which may offer rapid and durable B-cell depletion [86][91] Additional Insights - **Market Positioning**: AbbVie aims to position its products effectively in the market, leveraging data from ongoing studies to enhance treatment options for patients [68][86] - **Long-Term Strategy**: The company is focused on developing innovative therapies that address unmet medical needs in both HS and IBD, with a strong emphasis on combination therapies and novel mechanisms [56][60]